The role of CYFRA21-1,SCCA and NSE in the auxiliary diagnosis and prognosis of ovarian cancer
Objective To analyze CYFRA21-1,SCCA)and NSE in adjuvant diagnosis and prog-nosis assessment of ovarian cancer.Methods 131 patients with ovarian cancer who were treated at our hospi-tal from December 2020 to July 2022 were selected as the study subjects(observation group).Another 80 healthy patients who underwent physical examinations at our hospital during the same period were selected as the normal control group.Serum levels of CYFRA21-1,SCCA and NSE were also compared between the two groups.The serum levels of CYFRA21-1,SCCA and NSE in the observation group were compared in stages Ⅰ to Ⅱ and Ⅲ to Ⅳ.ROC curves were drawn to analyze the value of serum CYFRA21-1,SCCA,NSE alone,and combined detection for ovarian cancer.Logistic regression was used to analyze the single and multiple fac-tors affecting the prognosis of ovarian cancer.Results Serum levels of CYFRA21-1,SCCA,and NSE:the observation group before treatment>the observation group after treatment>the control group,the difference was statistically significant(P<0.05).The levels of CYFRA21-1,SCCA and NSE in the serum of patients in stages Ⅲ～Ⅳ were higher than those in stages Ⅰ～Ⅱ(P<0.05).The AUC of CYFRA21-1+SCCA+NSE in the diagnosis of ovarian cancer was 0.851,which was higher than that of CYFRA21-1,SCCA and NSE alone(P<0.05).After follow-up,52 patients had a poor prognosis,and 79 patients had a good prognosis.Logistic multivariate analysis showed that clinical stages Ⅲ～Ⅳ,CYFRA21-1>2.08 ng/mL,SCCA>1.50 μg/mL,NSE>12.50 ng/mL were independent risk factors for ovarian cancer prognosis(P<0.05).Conclusion Ovari-an cancer patients who underwent serum tests for CYFRA21-1,SCCA,and NSE can effectively enhance the accuracy of diagnosis and offer valuable insights for predicting patient prognosis in clinical settings.
NETL
NSTL
万方数据
